Life Sciences Maste Perceptive Acquires 85,104 Shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) Stock

Dova Pharmaceuticals Inc (NASDAQ:DOVA) major shareholder Life Sciences Maste Perceptive bought 85,104 shares of Dova Pharmaceuticals stock in a transaction on Thursday, July 11th. The shares were bought at an average cost of $16.68 per share, with a total value of $1,419,534.72. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Life Sciences Maste Perceptive also recently made the following trade(s):

  • On Friday, July 5th, Life Sciences Maste Perceptive bought 50,000 shares of Dova Pharmaceuticals stock. The shares were bought at an average cost of $16.46 per share, with a total value of $823,000.00.
  • On Wednesday, July 3rd, Life Sciences Maste Perceptive bought 20,541 shares of Dova Pharmaceuticals stock. The shares were bought at an average cost of $14.51 per share, with a total value of $298,049.91.
  • On Friday, June 28th, Life Sciences Maste Perceptive bought 427,209 shares of Dova Pharmaceuticals stock. The shares were bought at an average cost of $13.35 per share, with a total value of $5,703,240.15.

Shares of DOVA opened at $16.99 on Friday. The company has a market cap of $472.90 million, a P/E ratio of -6.53 and a beta of 2.56. The company has a current ratio of 4.46, a quick ratio of 4.27 and a debt-to-equity ratio of 0.20. The firm’s 50-day simple moving average is $11.35. Dova Pharmaceuticals Inc has a 12-month low of $5.62 and a 12-month high of $26.49.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.68) by $0.10. The firm had revenue of $4.00 million during the quarter, compared to the consensus estimate of $3.46 million. Dova Pharmaceuticals had a negative return on equity of 87.20% and a negative net margin of 521.67%. On average, equities research analysts expect that Dova Pharmaceuticals Inc will post -2.1 EPS for the current year.

A number of research firms have weighed in on DOVA. Zacks Investment Research lowered ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. HC Wainwright lifted their target price on Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, June 27th. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $69.00 target price on shares of Daimler in a report on Friday. BidaskClub upgraded Zillow Group from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 2nd. Finally, Wedbush set a $190.00 price target on Home Depot and gave the company a “hold” rating in a research report on Wednesday, May 22nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $28.56.

Several institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC boosted its position in shares of Dova Pharmaceuticals by 0.8% during the 1st quarter. FMR LLC now owns 1,347,521 shares of the company’s stock valued at $11,979,000 after acquiring an additional 10,970 shares during the last quarter. Sanders Morris Harris LLC lifted its position in Dova Pharmaceuticals by 85.1% in the 2nd quarter. Sanders Morris Harris LLC now owns 521,887 shares of the company’s stock worth $7,359,000 after buying an additional 239,972 shares during the last quarter. Sphera Funds Management LTD. lifted its position in Dova Pharmaceuticals by 54.2% in the 4th quarter. Sphera Funds Management LTD. now owns 185,000 shares of the company’s stock worth $1,402,000 after buying an additional 65,000 shares during the last quarter. Geode Capital Management LLC lifted its position in Dova Pharmaceuticals by 8.1% in the 4th quarter. Geode Capital Management LLC now owns 156,232 shares of the company’s stock worth $1,184,000 after buying an additional 11,732 shares during the last quarter. Finally, Spark Investment Management LLC lifted its position in Dova Pharmaceuticals by 31.8% in the 1st quarter. Spark Investment Management LLC now owns 80,500 shares of the company’s stock worth $715,000 after buying an additional 19,400 shares during the last quarter. Hedge funds and other institutional investors own 30.18% of the company’s stock.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Recommended Story: How Do You Calculate Return on Investment (ROI)?

Insider Buying and Selling by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.